Active ingredients: cetuximab
What it is used for
Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer. In combination with infusional 5-fluorouracil/folinic acid plus irinotecan. In combination with irinotecan in patients who are refractory to first-line chemotherapy. In first-line in combination with FOLFOX. As a single agent in patients who have failed or are intolerant to oxaliplatin-based therapy and irinotecan-based therapy. (See CLINICAL TRIALS) Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck. In combination with radiation therapy for locally advanced disease. In combination with platinum-based chemotherapy for recurrent and/or metastatic disease.
How to take it
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
- The way to take this medicine: Intravenous
- Store at 2 to 8 degrees Celsius
- Do not Freeze
- Shelf lifetime is 4 Years.
Always read the label. If symptoms persist see your healthcare professional.
Clear colourless solution that may contain product-related particles.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient cetuximab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems